{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T23:28:07Z","timestamp":1778801287082,"version":"3.51.4"},"reference-count":165,"publisher":"Bentham Science Publishers Ltd.","issue":"39","funder":[{"DOI":"10.13039\/501100004442","name":"National Science Centre, Poland","doi-asserted-by":"publisher","award":["2017\/25\/N\/NZ7\/00544"],"award-info":[{"award-number":["2017\/25\/N\/NZ7\/00544"]}],"id":[{"id":"10.13039\/501100004442","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2020,11,24]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Alzheimer\u2019s Disease (AD) is a chronic and progressive neurodegenerative disorder that\naffects over 46 million people worldwide. It is characterized by a decline in cognitive abilities, including\nmemory and thinking skills. AD patients also suffer from behavioral and psychological\nsymptoms of dementia of which depression is the most prevalent. Currently available drugs provide\nmodest symptomatic relief and do not reduce pathological hallmarks (senile plaques and neurofibrillary\ntangles) and neuroinflammation, both of which are integral parts of AD. Studies suggest that AD\nis a type of diabetes manifested in the brain. Although AD and diabetes are currently classified as\nseparate disease entities, they share common pathophysiological mechanisms, one of them is an increased\nlevel of cytokines involved in the inflammation and the regulation of metabolic, regenerative,\nand neural processes. The purpose of this review was to update the most recent reports on the discovery\nand development of antidiabetic agents as promising drugs for the symptomatic and diseasemodifying\ntreatment of AD. We collected the results of in vitro and in vivo studies, and recent reports\nfrom clinical trials suggesting the utility of antidiabetic agents in memory-enhancing therapy of AD.\nTheir beneficial effects on chronic neuroinflammation, pathological hallmarks, and neuropsychiatric\nsymptoms co-occurring with cognitive deficits are also presented. Antidiabetic agents refer to the\ndiabetic and inflammatory hypotheses of AD and provide hope to find an effective drug for comprehensive\ntherapy of the disease.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0929867326666191011144818","type":"journal-article","created":{"date-parts":[[2019,10,12]],"date-time":"2019-10-12T08:05:16Z","timestamp":1570867516000},"page":"6658-6681","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Diabetic Theory in Anti-Alzheimer\u2019s Drug Research and Development - Part 1: Therapeutic Potential of Antidiabetic Agents"],"prefix":"10.2174","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3595-7609","authenticated-orcid":true,"given":"Agnieszka","family":"Jankowska","sequence":"first","affiliation":[{"name":"Department of Medicinal Chemistry, Jagiellonian University Medical College, 9 Medyczna Street, 30-688 Krakow, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2383-3278","authenticated-orcid":true,"given":"Anna","family":"Weso\u0142owska","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Jagiellonian University Medical College, 9 Medyczna Street, 30-688 Krakow, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2445-9759","authenticated-orcid":true,"given":"Maciej","family":"Paw\u0142owski","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, Jagiellonian University Medical College, 9 Medyczna Street, 30-688 Krakow, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3819-7801","authenticated-orcid":true,"given":"Gra\u017cyna","family":"Ch\u0142o\u0144-Rzepa","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Jagiellonian University Medical College, 9 Medyczna Street, 30-688 Krakow, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.ncl.2007.03.008","volume":"25","author":"Kelley B.J.","year":"2007","unstructured":"Kelley B.J.; Petersen R.C.; Alzheimer\u2019s disease and mild cognitive impairment. Neurol Clin 2007,25(3),577-609, v.","journal-title":"Neurol Clin"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3389\/fneur.2012.00073","volume":"3","author":"Cerejeira J.","year":"2012","unstructured":"Cerejeira J.; Lagarto L.; Mukaetova-Ladinska E.B.; Behavioral and psychological symptoms of dementia. Front Neurol 2012,3,73","journal-title":"Front Neurol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"739","DOI":"10.3389\/fphar.2017.00739","volume":"8","author":"Mat Nuri T.H.","year":"2017","unstructured":"Mat Nuri T.H.; Hong Y.H.; Ming L.C.; Mohd Joffry S.; Othman M.F.; Neoh C.F.; Knowledge on Alzheimer\u2019s disease among public hospitals and health clinics pharmacists in the state of Selangor, Malaysia. Front Pharmacol 2017,8,739","journal-title":"Front Pharmacol"},{"key":"ref=4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0210958","volume":"14","author":"Cimler R.","year":"2019","unstructured":"Cimler R.; Maresova P.; Kuhnova J.; Kuca K.; Predictions of Alzheimer\u2019s disease treatment and care costs in European countries. PLoS One 2019,14(1)","journal-title":"PLoS One"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.3892\/mmr.2019.10374","volume":"20","author":"Sharma K.","year":"2019","unstructured":"Sharma K.; Cholinesterase inhibitors as Alzheimer\u2019s therapeutics.  (review) Mol Med Rep 2019,20(2),1479-1487","journal-title":"Mol Med Rep"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s00210-014-0966-4","volume":"387","author":"Ko\u0142aczkowski M.","year":"2014","unstructured":"Ko\u0142aczkowski M.; Mierzejewski P.; Bienkowski P.; Weso\u0142owska A.; Newman-Tancredi A.; Antipsychotic, antidepressant, and cognitive-impairment properties of antipsychotics: rat profile and implications for behavioral and psychological symptoms of dementia. Naunyn Schmiedebergs Arch Pharmacol 2014,387(6),545-557","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"e2986","DOI":"10.1136\/bmj.e2986","volume":"344","author":"Rodda J.","year":"2012","unstructured":"Rodda J.; Carter J.; Cholinesterase inhibitors and memantine for symptomatic treatment of dementia. BMJ 2012,344,e2986-e2986","journal-title":"BMJ"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"445","DOI":"10.3233\/JAD-130395","volume":"36","author":"Yang Z.","year":"2013","unstructured":"Yang Z.; Zhou X.; Zhang Q.; Effectiveness and safety of memantine treatment for Alzheimer\u2019s disease. J Alzheimers Dis 2013,36(3),445-458","journal-title":"J Alzheimers Dis"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s12974-018-1313-3","volume":"15","author":"Newcombe E.A.","year":"2018","unstructured":"Newcombe E.A.; Camats-Perna J.; Silva M.L.; Valmas N.; Huat T.J.; Medeiros R.; Inflammation: the link between comorbidities, genetics and Alzheimer\u2019s disease. J Neuroinflammation 2018,15(1),276","journal-title":"J Neuroinflammation"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","volume":"14","author":"Heneka M.T.","year":"2015","unstructured":"Heneka M.T.; Carson M.J.; El Khoury J.; Landreth G.E.; Brosseron F.; Feinstein D.L.; Jacobs A.H.; Wyss-Coray T.; Vitorica J.; Ransohoff R.M.; Herrup K.; Frautschy S.A.; Finsen B.; Brown G.C.; Verkhratsky A.; Yamanaka K.; Koistinaho J.; Latz E.; Halle A.; Petzold G.C.; Town T.; Morgan D.; Shinohara M.L.; Perry V.H.; Holmes C.; Bazan N.G.; Brooks D.J.; Hunot S.; Joseph B.; Deigendesch N.; Garaschuk O.; Boddeke E.; Dinarello C.A.; Breitner J.C.; Cole G.M.; Golenbock D.T.; Kummer M.P.; Neuroinflammation in Alzheimer\u2019s disease. Lancet Neurol 2015,14(4),388-405","journal-title":"Lancet Neurol"},{"key":"ref=11","first-page":"373","volume":"14","author":"Kroner Z.","year":"2009","unstructured":"Kroner Z.; The relationship between Alzheimer\u2019s disease and diabetes: type 3 diabetes? Altern Med Rev 2009,14(4),373-379","journal-title":"Altern Med Rev"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.2174\/1568026617666170103163403","volume":"17","author":"Leszek J.","year":"2017","unstructured":"Leszek J.; Trypka E.; Tarasov V.V.; Ashraf G.M.; Aliev G.; Type 3 diabetes mellitus: a novel implication of Alzheimers disease. Curr Top Med Chem 2017,17(12),1331-1335","journal-title":"Curr Top Med Chem"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/j.bbadis.2016.08.018","volume":"1863","author":"Kandimalla R.","year":"2017","unstructured":"Kandimalla R.; Thirumala V.; Reddy P.H.; Is Alzheimer\u2019s disease a type 3 diabetes? A critical appraisal. Biochim Biophys Acta Mol Basis Dis 2017,1863(5),1078-1089","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3233\/JAD-2005-8304","volume":"8","author":"Rivera E.J.","year":"2005","unstructured":"Rivera E.J.; Goldin A.; Fulmer N.; Tavares R.; Wands J.R.; de la Monte S.M.; Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer\u2019s disease: link to brain reductions in acetylcholine. J Alzheimers Dis 2005,8(3),247-268","journal-title":"J Alzheimers Dis"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/j.1651-2227.1994.tb13300.x","volume":"399","author":"Taylor S.I.","year":"1994","unstructured":"Taylor S.I.; Accili D.; Haft C.R.; Hone J.; Imai Y.; Levy-Toledano R.; Quon M.J.; Suzuki Y.; Wertheimer E.; Mechanisms of hormone resistance: lessons from insulin-resistant patients. Acta Paediatr Suppl 1994,399(s399),95-104","journal-title":"Acta Paediatr Suppl"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"571","DOI":"10.2174\/1871530319666190311141855","volume":"19","author":"Fiore V.","year":"2019","unstructured":"Fiore V.; De Rosa A.; Falasca P.; Marci M.; Guastamacchia E.; Licchelli B.; Giagulli V.A.; De Pergola G.; Poggi A.; Triggiani V.; Focus on the correlations between Alzheimer\u2019s disease and type 2 diabetes. Endocr Metab Immune Disord Drug Targets 2019,19(5),571-579","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/978-981-13-3540-2_8","volume":"1128","author":"Hanyu H.","year":"2019","unstructured":"Hanyu H.; Diabetes-related dementia. Adv Exp Med Biol 2019,1128,147-160","journal-title":"Adv Exp Med Biol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/nrneurol.2017.185","volume":"14","author":"Arnold S.E.","year":"2018","unstructured":"Arnold S.E.; Arvanitakis Z.; Macauley-Rambach S.L.; Koenig A.M.; Wang H-Y.; Ahima R.S.; Craft S.; Gandy S.; Buettner C.; Stoeckel L.E.; Holtzman D.M.; Nathan D.M.; Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums. Nat Rev Neurol 2018,14(3),168-181","journal-title":"Nat Rev Neurol"},{"key":"ref=19","doi-asserted-by":"publisher","DOI":"10.1186\/s12979-019-0147-x","volume":"16, 7.","author":"Massaccesi L.","year":"2019","unstructured":"Massaccesi L.; Galliera E.; Galimberti D.; Fenoglio C.; Arcaro M.; Goi G.; Barassi A.; Corsi Romanelli M.M.; Lag-time in Alzheimer\u2019s disease patients: a potential plasmatic oxidative stress marker associated with ApoE4 isoform. Immun ageing I A 2019,16, 7.","journal-title":"Immun ageing I A"},{"key":"ref=20","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/5953685","volume":"2019","author":"Bigagli E.","year":"2019","unstructured":"Bigagli E.; Lodovici M.; Circulating oxidative stress biomarkers in clinical studies on type 2 diabetes and its complications. Oxid Med Cell Longev 2019,2019","journal-title":"Oxid Med Cell Longev"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1007\/s00394-016-1212-2","volume":"55","author":"Stefano G.B.","year":"2016","unstructured":"Stefano G.B.; Challenger S.; Kream R.M.; Hyperglycemia-associated alterations in cellular signaling and dysregulated mitochondrial bioenergetics in human metabolic disorders. Eur J Nutr 2016,55(8),2339-2345","journal-title":"Eur J Nutr"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.neulet.2017.06.041","volume":"655","author":"Pintana H.","year":"2017","unstructured":"Pintana H.; Apaijai N.; Kerdphoo S.; Pratchayasakul W.; Sripetchwandee J.; Suntornsaratoon P.; Charoenphandhu N.; Chattipakorn N.; Chattipakorn S.C.; Hyperglycemia induced the Alzheimer\u2019s proteins and promoted loss of synaptic proteins in advanced-age female Goto-Kakizaki (GK) rats. Neurosci Lett 2017,655,41-45","journal-title":"Neurosci Lett"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1002\/ana.25570","volume":"86","author":"Martinez-Valbuena I.","year":"2019","unstructured":"Martinez-Valbuena I.; Valenti-Azcarate R.; Amat-Villegas I.; Riverol M.; Marcilla I.; de Andrea C.E.; S\u00e1nchez-Arias J.A.; Del Mar Carmona-Abellan M.; Marti G.; Erro M.E.; Mart\u00ednez-Vila E.; Tu\u00f1on M-T.; Luquin M-R.; Amylin as a potential link between type 2 diabetes and alzheimer disease. Ann Neurol 2019,86(4),539-551","journal-title":"Ann Neurol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"465","DOI":"10.4103\/0366-6999.151082","volume":"128","author":"Zhang Y-W.","year":"2015","unstructured":"Zhang Y-W.; Zhang J-Q.; Liu C.; Wei P.; Zhang X.; Yuan Q-Y.; Yin X-T.; Wei L-Q.; Cui J-G.; Wang J.; Memory dysfunction in type 2 diabetes mellitus correlates with reduced hippocampal CA1 and subiculum volumes. Chin Med J (Engl) 2015,128(4),465-471","journal-title":"Chin Med J (Engl)"},{"key":"ref=25","unstructured":"US National Library of Medicine. Available at:"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1001\/jama.292.18.2237","volume":"292","author":"Yaffe K.","year":"2004","unstructured":"Yaffe K.; Kanaya A.; Lindquist K.; Simonsick E.M.; Harris T.; Shorr R.I.; Tylavsky F.A.; Newman A.B.; The metabolic syndrome, inflammation and risk of cognitive decline. JAMA 2004,292(18),2237-2242","journal-title":"JAMA"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.neuint.2013.06.018","volume":"63","author":"Languren G.","year":"2013","unstructured":"Languren G.; Montiel T.; Julio-Amilpas A.; Massieu L.; Neuronal damage and cognitive impairment associated with hypoglycemia: an integrated view. Neurochem Int 2013,63(4),331-343","journal-title":"Neurochem Int"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1177\/2040622315608646","volume":"6","author":"Atkin S.","year":"2015","unstructured":"Atkin S.; Javed Z.; Fulcher G.; Insulin degludec and insulin aspart: novel insulins for the management of diabetes mellitus. Ther Adv Chronic Dis 2015,6(6),375-388","journal-title":"Ther Adv Chronic Dis"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1093\/gerona\/glw065","volume":"72","author":"Anderson K.L.","year":"2017","unstructured":"Anderson K.L.; Frazier H.N.; Maimaiti S.; Bakshi V.V.; Majeed Z.R.; Brewer L.D.; Porter N.M.; Lin A-L.; Thibault O.; Impact of single or repeated dose intranasal zinc-free insulin in young and aged F344 rats on cognition, signaling and brain metabolism. J Gerontol A Biol Sci Med Sci 2017,72(2),189-197","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12974-015-0282-z","volume":"12","author":"Adzovic L.","year":"2015","unstructured":"Adzovic L.; Lynn A.E.; D\u2019Angelo H.M.; Crockett A.M.; Kaercher R.M.; Royer S.E.; Hopp S.C.; Wenk G.L.; Insulin improves memory and reduces chronic neuroinflammation in the hippocampus of young but not aged brains. J Neuroinflammation 2015,12(1),63","journal-title":"J Neuroinflammation"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.bbr.2008.09.008","volume":"196","author":"Akanmu M.A.","year":"2009","unstructured":"Akanmu M.A.; Nwabudike N.L.; Ilesanmi O.R.; Analgesic, learning and memory and anxiolytic effects of insulin in mice. Behav Brain Res 2009,196(2),237-241","journal-title":"Behav Brain Res"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.brainresbull.2018.09.017","volume":"143","author":"Mueller P.L.","year":"2018","unstructured":"Mueller P.L.; Pritchett C.E.; Wiechman T.N.; Zharikov A.; Hajnal A.; Antidepressant-like effects of insulin and IGF-1 are mediated by IGF-1 receptors in the brain. Brain Res Bull 2018,143,27-35","journal-title":"Brain Res Bull"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"5351","DOI":"10.2174\/0929867326666190620095623","volume":"27","author":"Jankowska A.","year":"2020","unstructured":"Jankowska A.; Weso\u0142owska A.; Paw\u0142owski M.; Ch\u0142o\u0144-Rzepa G.; Multifunctional ligands targeting phosphodiesterase as the future strategy for the symptomatic and disease-modifying treatment of Alzheimer\u2019s disease. Curr Med Chem 2020,27(32),5351-5373","journal-title":"Curr Med Chem"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.2174\/0929867324666170529122802","volume":"25","author":"Jankowska A.","year":"2018","unstructured":"Jankowska A.; Weso\u0142owska A.; Paw\u0142owski M.; Ch\u0142o\u0144-Rzepa G.; Multi-target-directed ligands affecting serotonergic neurotransmission for Alzheimer\u2019s disease therapy: advances in chemical and biological research. Curr Med Chem 2018,25(17),2045-2067","journal-title":"Curr Med Chem"},{"key":"ref=35","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/674164","volume":"2014","author":"Nampoothiri M.","year":"2014","unstructured":"Nampoothiri M.; Reddy N.D.; John J.; Kumar N.; Kutty Nampurath G.; Rao Chamallamudi M.; Insulin blocks glutamate-induced neurotoxicity in differentiated SH-SY5Y neuronal cells. Behav Neurol 2014,2014","journal-title":"Behav Neurol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"3561","DOI":"10.1073\/pnas.051634698","volume":"98","author":"Skeberdis V.A.","year":"2001","unstructured":"Skeberdis V.A.; Lan J.; Zheng X.; Zukin R.S.; Bennett M.V.L.; Insulin promotes rapid delivery of N-methyl-D- aspartate receptors to the cell surface by exocytosis. Proc Natl Acad Sci USA 2001,98(6),3561-3566","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"8543","DOI":"10.1038\/ncomms9543","volume":"6","author":"Stouffer M.A.","year":"2015","unstructured":"Stouffer M.A.; Woods C.A.; Patel J.C.; Lee C.R.; Witkovsky P.; Bao L.; Machold R.P.; Jones K.T.; de Vaca S.C.; Reith M.E.A.; Carr K.D.; Rice M.E.; Insulin enhances striatal dopamine release by activating cholinergic interneurons and thereby signals reward. Nat Commun 2015,6,8543","journal-title":"Nat Commun"},{"key":"ref=38","doi-asserted-by":"publisher","DOI":"10.1016\/j.physbeh.2019.112640","volume":"211","author":"Yarube I.","year":"2019","unstructured":"Yarube I.; Ayo J.; Magaji R.; Umar I.; Insulin treatment increases brain nitric oxide and oxidative stress, but does not affect memory function in mice. Physiol Behav 2019,211","journal-title":"Physiol Behav"},{"key":"ref=39","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2019.104541","volume":"132","author":"Kim B.","year":"2019","unstructured":"Kim B.; Elzinga S.E.; Henn R.E.; McGinley L.M.; Feldman E.L.; The effects of insulin and insulin-like growth factor I on amyloid precursor protein phosphorylation in in vitro and in vivo models of Alzheimer\u2019s disease. Neurobiol Dis 2019,132","journal-title":"Neurobiol Dis"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1016\/j.jalz.2013.12.004","volume":"10","author":"De Felice F.G.","year":"2014","unstructured":"De Felice F.G.; Lourenco M.V.; Ferreira S.T.; How does brain insulin resistance develop in Alzheimer\u2019s disease? Alzheimers Dement 2014,10(Suppl. 1),S26-S32","journal-title":"Alzheimers Dement"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.2147\/DDDT.S141675","volume":"11","author":"Wang Y-W.","year":"2017","unstructured":"Wang Y-W.; He S-J.; Feng X.; Cheng J.; Luo Y-T.; Tian L.; Huang Q.; Metformin: a review of its potential indications. Drug Des Devel Ther 2017,11,2421-2429","journal-title":"Drug Des Devel Ther"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"196","DOI":"10.2174\/1871530315666150316124019","volume":"15","author":"Saisho Y.","year":"2015","unstructured":"Saisho Y.; Metformin and inflammation: Its potential beyond glucose-lowering effect. Endocr Metab Immune Disord Drug Targets 2015,15(3),196-205","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S1734-1140(10)70357-1","volume":"62","author":"\u0141abuzek K.","year":"2010","unstructured":"\u0141abuzek K.; Suchy D.; Gabryel B.; Bielecka A.; Liber S.; Okopie\u0144 B.; Quantification of metformin by the HPLC method in brain regions, cerebrospinal fluid and plasma of rats treated with lipopolysaccharide. Pharmacol Rep 2010,62(5),956-965","journal-title":"Pharmacol Rep"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.brainres.2016.05.013","volume":"1644","author":"Oliveira W.H.","year":"2016","unstructured":"Oliveira W.H.; Nunes A.K.; Fran\u00e7a M.E.R.; Santos L.A.; L\u00f3s D.B.; Rocha S.W.; Barbosa K.P.; Rodrigues G.B.; Peixoto C.A.; Effects of metformin on inflammation and short-term memory in streptozotocin-induced diabetic mice. Brain Res 2016,1644,149-160","journal-title":"Brain Res"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.expneurol.2018.09.008","volume":"311","author":"Chen J-L.","year":"2019","unstructured":"Chen J-L.; Luo C.; Pu D.; Zhang G-Q.; Zhao Y-X.; Sun Y.; Zhao K-X.; Liao Z-Y.; Lv A-K.; Zhu S-Y.; Zhou J.; Xiao Q.; Metformin attenuates diabetes-induced tau hyperphosphorylation in vitro and in vivo by enhancing autophagic clearance. Exp Neurol 2019,311,44-56","journal-title":"Exp Neurol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.bbi.2017.12.009","volume":"69","author":"Ou Z.","year":"2018","unstructured":"Ou Z.; Kong X.; Sun X.; He X.; Zhang L.; Gong Z.; Huang J.; Xu B.; Long D.; Li J.; Li Q.; Xu L.; Xuan A.; Metformin treatment prevents amyloid plaque deposition and memory impairment in APP\/PS1 mice. Brain Behav Immun 2018,69,351-363","journal-title":"Brain Behav Immun"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"19","DOI":"10.22038\/IJBMS.2017.24331.6071","volume":"21","author":"Fatemi I.","year":"2018","unstructured":"Fatemi I.; Khaluoi A.; Kaeidi A.; Shamsizadeh A.; Heydari S.; Allahtavakoli M.A.; Protective effect of metformin on D-galactose-induced aging model in mice. Iran J Basic Med Sci 2018,21(1),19-25","journal-title":"Iran J Basic Med Sci"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"416","DOI":"10.5455\/njppp.2015.5.1208201564","volume":"5","author":"Ashrostaghi Z.","year":"2015","unstructured":"Ashrostaghi Z.; Ganji F.; Sepehri H.; Effect of metformin on the spatial memory in aged rats. Natl J Physiol Pharm Pharmacol 2015,5(5),416","journal-title":"Natl J Physiol Pharm Pharmacol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.pharep.2019.04.015","volume":"71","author":"Aksoz E.","year":"2019","unstructured":"Aksoz E.; Gocmez S.S.; Sahin T.D.; Aksit D.; Aksit H.; Utkan T.; The protective effect of metformin in scopolamine-induced learning and memory impairment in rats. Pharmacol Rep 2019,71(5),818-825","journal-title":"Pharmacol Rep"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.3233\/JAD-181240","volume":"68","author":"Farr S.A.","year":"2019","unstructured":"Farr S.A.; Roesler E.; Niehoff M.L.; Roby D.A.; McKee A.; Morley J.E.; Metformin improves learning and memory in the SAMP8 mouse model of Alzheimer\u2019s disease. J Alzheimers Dis 2019,68(4),1699-1710","journal-title":"J Alzheimers Dis"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"7748","DOI":"10.1096\/fj.201802718R","volume":"33","author":"Zhang J.","year":"2019","unstructured":"Zhang J.; Lin Y.; Dai X.; Fang W.; Wu X.; Chen X.; Metformin treatment improves the spatial memory of aged mice in an APOE genotype-dependent manner. FASEB J 2019,33(6),7748-7757","journal-title":"FASEB J"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/bph.14519","volume":"176","author":"Fan J.","year":"2019","unstructured":"Fan J.; Li D.; Chen H-S.; Huang J-G.; Xu J-F.; Zhu W-W.; Chen J-G.; Wang F.; Metformin produces anxiolytic-like effects in rats by facilitating GABAA receptor trafficking to membrane. Br J Pharmacol 2019,176(2),297-316","journal-title":"Br J Pharmacol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/1440-1681.12265","volume":"41","author":"Guo M.","year":"2014","unstructured":"Guo M.; Mi J.; Jiang Q-M.; Xu J-M.; Tang Y-Y.; Tian G.; Wang B.; Metformin may produce antidepressant effects through improvement of cognitive function among depressed patients with diabetes mellitus. Clin Exp Pharmacol Physiol 2014,41(9),650-656","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s00210-018-1466-8","volume":"391","author":"Khedr S.A.","year":"2018","unstructured":"Khedr S.A.; Elmelgy A.A.; El-Kharashi O.A.; Abd-Alkhalek H.A.; Louka M.L.; Sallam H.A.; Aboul-Fotouh S.; Metformin potentiates cognitive and antidepressant effects of fluoxetine in rats exposed to chronic restraint stress and high fat diet: potential involvement of hippocampal c-Jun repression. Naunyn Schmiedebergs Arch Pharmacol 2018,391(4),407-422","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"S54","DOI":"10.1016\/j.euroneuro.2017.12.082","volume":"28","author":"Matte Bon G.","year":"2018","unstructured":"Matte Bon G.; Poggini S.; Viglione A.; Milior G.; Golia M.T.; Alboni S.; Maggi L.; Branchi I.; Combined treatment fluoxetine and metformin potentiates antidepressant efficacy: the differential involvement of the dorsal and ventral hippocampus. Eur Neuropsychopharmacol 2018,28,S54-S55","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.brainres.2019.05.023","volume":"1719","author":"Wang X.","year":"2019","unstructured":"Wang X.; Luo C.; Mao X-Y.; Li X.; Yin J-Y.; Zhang W.; Zhou H-H.; Liu Z-Q.; Metformin reverses the schizophrenia-like behaviors induced by MK-801 in rats. Brain Res 2019,1719,30-39","journal-title":"Brain Res"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"37","DOI":"10.14336\/AD.2017.1202","volume":"10","author":"Chin-Hsiao T.","year":"2019","unstructured":"Chin-Hsiao T.; Metformin and the risk of dementia in type 2 diabetes patients. Aging Dis 2019,10(1),37-48","journal-title":"Aging Dis"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"227","DOI":"10.3389\/fnagi.2018.00227","volume":"10","author":"Lin Y.","year":"2018","unstructured":"Lin Y.; Wang K.; Ma C.; Wang X.; Gong Z.; Zhang R.; Zang D.; Cheng Y.; Evaluation of metformin on cognitive improvement in patients with non-dementia vascular cognitive impairment and abnormal glucose metabolism. Front Aging Neurosci 2018,10,227","journal-title":"Front Aging Neurosci"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1089\/cap.2017.0072","volume":"28","author":"Aman M.G.","year":"2018","unstructured":"Aman M.G.; Hollway J.A.; Veenstra-VanderWeele J.; Handen B.L.; Sanders K.B.; Chan J.; Macklin E.; Arnold L.E.; Wong T.; Newsom C.; Hastie Adams R.; Marler S.; Peleg N.; Anagnostou E.A.; Effects of metformin on spatial and verbal memory in children with ASD and overweight associated with atypical antipsychotic use. J Child Adolesc Psychopharmacol 2018,28(4),266-273","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.pnpbp.2017.06.002","volume":"79","author":"Kuan Y-C.","year":"2017","unstructured":"Kuan Y-C.; Huang K-W.; Lin C-L.; Hu C-J.; Kao C-H.; Effects of metformin exposure on neurodegenerative diseases in elderly patients with type 2 diabetes mellitus Prog. Neuro-psychopharmacol Biol Psychiatry 2017,79(Pt B),77-83","journal-title":"Neuro-psychopharmacol Biol Psychiatry"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.3390\/molecules24142545","volume":"24","author":"Hong F.","year":"2019","unstructured":"Hong F.; Pan S.; Guo Y.; Xu P.; Zhai Y.; PPARs as nuclear receptors for nutrient and energy metabolism. Molecules 2019,24(14),2545","journal-title":"Molecules"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.2174\/1381612825666190716094852","volume":"25","author":"Ahsan W.","year":"2019","unstructured":"Ahsan W.; The journey of thiazolidinediones as modulators of PPARs for the management of diabetes: a current perspective. Curr Pharm Des 2019,25(23),2540-2554","journal-title":"Curr Pharm Des"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"232","DOI":"10.2174\/1570159X16666180828100002","volume":"17","author":"Khan M.A.","year":"2019","unstructured":"Khan M.A.; Alam Q.; Haque A.; Ashafaq M.; Khan M.J.; Ashraf G.M.; Ahmad M.; Current progress on peroxisome proliferator-activated receptor gamma agonist as an emerging therapeutic approach for the treatment of Alzheimer\u2019s disease: an update. Curr Neuropharmacol 2019,17(3),232-246","journal-title":"Curr Neuropharmacol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1038\/npp.2010.32","volume":"35","author":"Escribano L.","year":"2010","unstructured":"Escribano L.; Sim\u00f3n A-M.; Gimeno E.; Cuadrado-Tejedor M.; L\u00f3pez de Maturana R.; Garc\u00eda-Osta A.; Ricobaraza A.; P\u00e9rez-Mediavilla A.; Del R\u00edo J.; Frechilla D.; Rosiglitazone rescues memory impairment in Alzheimer\u2019s transgenic mice: mechanisms involving a reduced amyloid and tau pathology. Neuropsychopharmacology 2010,35(7),1593-1604","journal-title":"Neuropsychopharmacology"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.nbd.2010.07.005","volume":"40","author":"Yoon S-Y.","year":"2010","unstructured":"Yoon S-Y.; Park J-S.; Choi J-E.; Choi J-M.; Lee W-J.; Kim S-W.; Kim D-H.; Rosiglitazone reduces tau phosphorylation via JNK inhibition in the hippocampus of rats with type 2 diabetes and tau transfected SH-SY5Y cells. Neurobiol Dis 2010,40(2),449-455","journal-title":"Neurobiol Dis"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/j.2042-7158.2011.01432.x","volume":"64","author":"Xiang G.Q.","year":"2012","unstructured":"Xiang G.Q.; Tang S.S.; Jiang L.Y.; Hong H.; Li Q.; Wang C.; Wang X.Y.; Zhang T.T.; Yin L.; PPAR\u03b3 agonist pioglitazone improves scopolamine-induced memory impairment in mice. J Pharm Pharmacol 2012,64(4),589-596","journal-title":"J Pharm Pharmacol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/j.1472-8206.2009.00708.x","volume":"23","author":"Kaur B.","year":"2009","unstructured":"Kaur B.; Singh N.; Jaggi A.S.; Exploring mechanism of pioglitazone-induced memory restorative effect in experimental dementia. Fundam Clin Pharmacol 2009,23(5),557-566","journal-title":"Fundam Clin Pharmacol"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.neulet.2017.04.052","volume":"651","author":"Gao F.","year":"2017","unstructured":"Gao F.; Zang L.; Wu D.Y.; Li Y.J.; Zhang Q.; Wang H.B.; Tian G.L.; Mu Y.M.; Pioglitazone improves the ability of learning and memory via activating ERK1\/2 signaling pathway in the hippocampus of T2DM rats. Neurosci Lett 2017,651,165-170","journal-title":"Neurosci Lett"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.neulet.2014.06.010","volume":"578","author":"Xu S.","year":"2014","unstructured":"Xu S.; Guan Q.; Wang C.; Wei X.; Chen X.; Zheng B.; An P.; Zhang J.; Chang L.; Zhou W.; Mody I.; Wang Q.; Rosiglitazone prevents the memory deficits induced by amyloid-beta oligomers via inhibition of inflammatory responses. Neurosci Lett 2014,578,7-11","journal-title":"Neurosci Lett"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13098-019-0432-z","volume":"11","author":"Li J.","year":"2019","unstructured":"Li J.; Shen X.; Effect of rosiglitazone on inflammatory cytokines and oxidative stress after intensive insulin therapy in patients with newly diagnosed type 2 diabetes. Diabetol Metab Syndr 2019,11,35","journal-title":"Diabetol Metab Syndr"},{"key":"ref=71","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/7915730","volume":"2019","author":"Xia L.","year":"2019","unstructured":"Xia L.; Liu J.; Sun Y.; Shi H.; Yang G.; Feng Y.; Yin S.; Rosiglitazone improves glucocorticoid resistance in a sudden sensorineural hearing loss by promoting MAP kinase phosphatase-1 Expression. Mediators Inflamm 2019,2019","journal-title":"Mediators Inflamm"},{"key":"ref=72","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/6386729","volume":"2019","author":"Meng Q-Q.","year":"2019","unstructured":"Meng Q-Q.; Feng Z-C.; Zhang X-L.; Hu L-Q.; Wang M.; Zhang H-F.; Li S-M.; PPAR-\u03b3 activation exerts an anti-inflammatory effect by suppressing the NLRP3 inflammasome in spinal cord-derived neurons. Mediators Inflamm 2019,2019","journal-title":"Mediators Inflamm"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1038\/s41598-018-38336-2","volume":"9","author":"Kadam L.","year":"2019","unstructured":"Kadam L.; Kilburn B.; Baczyk D.; Kohan-Ghadr H.R.; Kingdom J.; Drewlo S.; Rosiglitazone blocks first trimester in-vitro placental injury caused by NF-\u03baB-mediated inflammation. Sci Rep 2019,9(1),2018","journal-title":"Sci Rep"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s10753-018-0940-2","volume":"42","author":"Zhao Y.","year":"2019","unstructured":"Zhao Y.; Wei X.; Song J.; Zhang M.; Huang T.; Qin J.; Peroxisome proliferator-activated receptor \u03b3 agonist rosiglitazone protects blood-brain barrier integrity following diffuse axonal injury by decreasing the levels of inflammatory mediators through a caveolin-1-dependent pathway. Inflammation 2019,42(3),841-856","journal-title":"Inflammation"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/j.1471-4159.2006.03758.x","volume":"97","author":"Luo Y.","year":"2006","unstructured":"Luo Y.; Yin W.; Signore A.P.; Zhang F.; Hong Z.; Wang S.; Graham S.H.; Chen J.; Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. J Neurochem 2006,97(2),435-448","journal-title":"J Neurochem"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1179\/016164110X12556180206112","volume":"32","author":"Zhang Q.","year":"2010","unstructured":"Zhang Q.; Hu W.; Meng B.; Tang T.; PPAR\u03b3 agonist rosiglitazone is neuroprotective after traumatic spinal cord injury via anti-inflammatory in adult rats. Neurol Res 2010,32(8),852-859","journal-title":"Neurol Res"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"6591","DOI":"10.3892\/mmr.2015.4292","volume":"12","author":"Yao J.","year":"2015","unstructured":"Yao J.; Zheng K.; Zhang X.; Rosiglitazone exerts neuroprotective effects via the suppression of neuronal autophagy and apoptosis in the cortex following traumatic brain injury. Mol Med Rep 2015,12(5),6591-6597","journal-title":"Mol Med Rep"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1089\/neu.2015.4361","volume":"34","author":"Liu M.","year":"2017","unstructured":"Liu M.; Bachstetter A.D.; Cass W.A.; Lifshitz J.; Bing G.; Pioglitazone attenuates neuroinflammation and promotes dopaminergic neuronal survival in the nigrostriatal system of rats after diffuse brain injury. J Neurotrauma 2017,34(2),414-422","journal-title":"J Neurotrauma"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.bbr.2012.03.006","volume":"231","author":"Almasi-Nasrabadi M.","year":"2012","unstructured":"Almasi-Nasrabadi M.; Javadi-Paydar M.; Mahdavian S.; Babaei R.; Sharifian M.; Norouzi A.; Dehpour A.R.; Involvement of NMDA receptors in the beneficial effects of pioglitazone on scopolamine-induced memory impairment in mice. Behav Brain Res 2012,231(1),138-145","journal-title":"Behav Brain Res"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s00213-012-2722-0","volume":"223","author":"Salehi-Sadaghiani M.","year":"2012","unstructured":"Salehi-Sadaghiani M.; Javadi-Paydar M.; Gharedaghi M.H.; Zandieh A.; Heydarpour P.; Yousefzadeh-Fard Y.; Dehpour A.R.; NMDA receptor involvement in antidepressant-like effect of pioglitazone in the forced swimming test in mice. Psychopharmacology (Berl) 2012,223(3),345-355","journal-title":"Psychopharmacology (Berl)"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/ana.24439","volume":"78","author":"Heneka M.T.","year":"2015","unstructured":"Heneka M.T.; Fink A.; Doblhammer G.; Effect of pioglitazone medication on the incidence of dementia. Ann Neurol 2015,78(2),284-294","journal-title":"Ann Neurol"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.jdiacomp.2017.01.006","volume":"31","author":"Chou P-S.","year":"2017","unstructured":"Chou P-S.; Ho B-L.; Yang Y-H.; Effects of pioglitazone on the incidence of dementia in patients with diabetes. J Diabetes Complications 2017,31(6),1053-1057","journal-title":"J Diabetes Complications"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1007\/s00125-017-4499-5","volume":"61","author":"Lu C-H.","year":"2018","unstructured":"Lu C-H.; Yang C-Y.; Li C-Y.; Hsieh C-Y.; Ou H-T.; Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy: a population-based longitudinal study. Diabetologia 2018,61(3),562-573","journal-title":"Diabetologia"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.trci.2019.05.004","volume":"5","author":"Knodt A.R.","year":"2019","unstructured":"Knodt A.R.; Burke J.R.; Welsh-Bohmer K.A.; Plassman B.L.; Burns D.K.; Brannan S.K.; Kukulka M.; Wu J.; Hariri A.R.; Effects of pioglitazone on mnemonic hippocampal function: A blood oxygen level-dependent functional magnetic resonance imaging study in elderly adults. Alzheimers Dement (N Y) 2019,5,254-263","journal-title":"Alzheimers Dement (N Y)"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1001\/archneurol.2010.229","volume":"68","author":"Geldmacher D.S.","year":"2011","unstructured":"Geldmacher D.S.; Fritsch T.; McClendon M.J.; Landreth G.; A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease. Arch Neurol 2011,68(1),45-50","journal-title":"Arch Neurol"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1159\/000318845","volume":"30","author":"Gold M.","year":"2010","unstructured":"Gold M.; Alderton C.; Zvartau-Hind M.; Egginton S.; Saunders A.M.; Irizarry M.; Craft S.; Landreth G.; Linnam\u00e4gi U.; Sawchak S.; Rosiglitazone monotherapy in mild-to-moderate Alzheimer\u2019s disease: results from a randomized, double-blind, placebo-controlled phase III study. Dement Geriatr Cogn Disord 2010,30(2),131-146","journal-title":"Dement Geriatr Cogn Disord"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1056\/NEJMp1309610","volume":"369","author":"Hiatt W.R.","year":"2013","unstructured":"Hiatt W.R.; Kaul S.; Smith R.J.; The cardiovascular safety of diabetes drugs--insights from the rosiglitazone experience. N Engl J Med 2013,369(14),1285-1287","journal-title":"N Engl J Med"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ejps.2019.01.008","volume":"129","author":"Silva-Abreu M.","year":"2019","unstructured":"Silva-Abreu M.; Gonzalez-Pizarro R.; Espinoza L.C.; Rodr\u00edguez-Lagunas M.J.; Espina M.; Garc\u00eda M.L.; Calpena A.C.; Thiazolidinedione as an alternative to facilitate oral administration in geriatric patients with Alzheimer\u2019s disease. Eur J Pharm Sci 2019,129,173-180","journal-title":"Eur J Pharm Sci"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"281","DOI":"10.15171\/apb.2019.032","volume":"9","author":"Chappidi S.R.","year":"2019","unstructured":"Chappidi S.R.; Bhargav E.; Marikunte V.; Chinthaginjala H.; Vijaya Jyothi M.; Pisay M.; Jutur M.; Shaik Mahammad M.; Poura M.; Yadav S.; Syed M.; A cost effective (QbD) approach in the development and optimization of rosiglitazone maleate mucoadhesive extended release tablets -in vitro and ex vivo. Adv Pharm Bull 2019,9(2),281-288","journal-title":"Adv Pharm Bull"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"39654","DOI":"10.1155\/2007\/39654","volume":"2007","author":"Erol A.","year":"2007","unstructured":"Erol A.; The functions of PPARs in aging and longevity. PPAR Res 2007,2007,39654","journal-title":"PPAR Res"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.4103\/1673-5374.165313","volume":"10","author":"Moreno S.","year":"2015","unstructured":"Moreno S.; Cer\u00f9 M.P.; In search for novel strategies towards neuroprotection and neuroregeneration: is PPAR\u03b1 a promising therapeutic target? Neural Regen Res 2015,10(9),1409-1412","journal-title":"Neural Regen Res"},{"key":"ref=92","first-page":"680","volume":"4","year":"2017","unstructured":"Krishna; Vaseem, A.; Sah, R.K.; Ali, M. Saroglitazar: a novel dual acting peroxisome proliferator activated receptor (PPAR) in dyslipidemia associated with T2DM. EJPMR 2017,4(2),680-684","journal-title":"EJPMR"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.apsb.2017.05.005","volume":"7","author":"Rigano D.","year":"2017","unstructured":"Rigano D.; Sirignano C.; Taglialatela-Scafati O.; The potential of natural products for targeting PPAR\u03b1. Acta Pharm Sin B 2017,7(4),427-438","journal-title":"Acta Pharm Sin B"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1055\/s-2007-979837","volume":"28","author":"Ashcroft F.M.","year":"1996","unstructured":"Ashcroft F.M.; Mechanisms of the glycaemic effects of sulfonylureas. Horm Metab Res 1996,28(9),456-463","journal-title":"Horm Metab Res"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"340","DOI":"10.4093\/dmj.2011.35.4.340","volume":"35","author":"Lee K.W.","year":"2011","unstructured":"Lee K.W.; Ku Y.H.; Kim M.; Ahn B.Y.; Chung S.S.; Park K.S.; Effects of sulfonylureas on peroxisome proliferator-activated receptor \u03b3 activity and on glucose uptake by thiazolidinediones. Diabetes Metab J 2011,35(4),340-347","journal-title":"Diabetes Metab J"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ejphar.2010.05.030","volume":"641","author":"Baraka A.","year":"2010","unstructured":"Baraka A.; ElGhotny S.; Study of the effect of inhibiting galanin in Alzheimer\u2019s disease induced in rats. Eur J Pharmacol 2010,641(2-3),123-127","journal-title":"Eur J Pharmacol"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1007\/s11064-016-1859-3","volume":"41","author":"Rizvi S.M.D.","year":"2016","unstructured":"Rizvi S.M.D.; Shaikh S.; Naaz D.; Shakil S.; Ahmad A.; Haneef M.; Abuzenadah A.M.; Kinetics and molecular docking study of an anti-diabetic drug glimepiride as acetylcholinesterase inhibitor: implication for Alzheimer\u2019s disease-diabetes dual therapy. Neurochem Res 2016,41(6),1475-1482","journal-title":"Neurochem Res"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.neulet.2013.10.052","volume":"557","author":"Liu F.","year":"2013","unstructured":"Liu F.; Wang Y.; Yan M.; Zhang L.; Pang T.; Liao H.;  Glimepiride attenuates A\u03b2 production via suppressing BACE1 activity in cortical neurons Neurosci Lett 2013,557(Pt B),90-94","journal-title":"Glimepiride attenuates A\u03b2 production via suppressing BACE1 activity in cortical neurons Neurosci Lett"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.atherosclerosis.2012.11.016","volume":"226","author":"Ling M-Y.","year":"2013","unstructured":"Ling M-Y.; Ma Z-Y.; Wang Y-Y.; Qi J.; Liu L.; Li L.; Zhang Y.; Up-regulated ATP-sensitive potassium channels play a role in increased inflammation and plaque vulnerability in macrophages. Atherosclerosis 2013,226(2),348-355","journal-title":"Atherosclerosis"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jphs.2017.09.032","volume":"135","author":"Tamura K.","year":"2017","unstructured":"Tamura K.; Ishikawa G.; Yoshie M.; Ohneda W.; Nakai A.; Takeshita T.; Tachikawa E.; Glibenclamide inhibits NLRP3 inflammasome-mediated IL-1\u03b2 secretion in human trophoblasts. J Pharmacol Sci 2017,135(2),89-95","journal-title":"J Pharmacol Sci"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/s41598-017-18785-x","volume":"8","author":"Lin Y-W.","year":"2018","unstructured":"Lin Y-W.; Liu P-S.; Pook K.A.; Wei L-N.; Glyburide and retinoic acid synergize to promote wound healing by anti-inflammation and RIP140 degradation. Sci Rep 2018,8(1),834","journal-title":"Sci Rep"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.1038\/srep03363","volume":"3","author":"Kewcharoenwong C.","year":"2013","unstructured":"Kewcharoenwong C.; Rinchai D.; Utispan K.; Suwannasaen D.; Bancroft G.J.; Ato M.; Lertmemongkolchai G.; Glibenclamide reduces pro-inflammatory cytokine production by neutrophils of diabetes patients in response to bacterial infection. Sci Rep 2013,3(1),3363","journal-title":"Sci Rep"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/fcp.12434","volume":"33","author":"Ishola I.O.","year":"2019","unstructured":"Ishola I.O.; Akataobi O.E.; Alade A.A.; Adeyemi O.O.; Glimepiride prevents paraquat-induced Parkinsonism in mice: involvement of oxidative stress and neuroinflammation. Fundam Clin Pharmacol 2019,33(3),277-285","journal-title":"Fundam Clin Pharmacol"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.brainresbull.2018.01.001","volume":"137","author":"Esmaeili M.H.","year":"2018","unstructured":"Esmaeili M.H.; Bahari B.; Salari A-A.; ATP-sensitive potassium-channel inhibitor glibenclamide attenuates HPA axis hyperactivity, depression- and anxiety-related symptoms in a rat model of Alzheimer\u2019s disease. Brain Res Bull 2018,137,265-276","journal-title":"Brain Res Bull"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"485","DOI":"10.3233\/JAD-2011-101524","volume":"24","author":"Hsu C-C.","year":"2011","unstructured":"Hsu C-C.; Wahlqvist M.L.; Lee M-S.; Tsai H-N.; Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin. J Alzheimers Dis 2011,24(3),485-493","journal-title":"J Alzheimers Dis"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/jcbfm.2012.166","volume":"33","author":"Ortega F.J.","year":"2013","unstructured":"Ortega F.J.; Jolkkonen J.; Mahy N.; Rodr\u00edguez M.J.; Glibenclamide enhances neurogenesis and improves long-term functional recovery after transient focal cerebral ischemia. J Cereb Blood Flow Metab 2013,33(3),356-364","journal-title":"J Cereb Blood Flow Metab"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1161\/STROKEAHA.108.522409","volume":"40","author":"Simard J.M.","year":"2009","unstructured":"Simard J.M.; Yurovsky V.; Tsymbalyuk N.; Melnichenko L.; Ivanova S.; Gerzanich V.; Protective effect of delayed treatment with low-dose glibenclamide in three models of ischemic stroke. Stroke 2009,40(2),604-609","journal-title":"Stroke"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.brainresbull.2018.06.006","volume":"142","author":"Zhou F.","year":"2018","unstructured":"Zhou F.; Liu Y.; Yang B.; Hu Z.; Neuroprotective potential of glibenclamide is mediated by antioxidant and anti-apoptotic pathways in intracerebral hemorrhage. Brain Res Bull 2018,142,18-24","journal-title":"Brain Res Bull"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.neurobiolaging.2017.12.009","volume":"64","author":"Bomba M.","year":"2018","unstructured":"Bomba M.; Granzotto A.; Castelli V.; Massetti N.; Silvestri E.; Canzoniero L.M.T.; Cimini A.; Sensi S.L.; Exenatide exerts cognitive effects by modulating the BDNF-TrkB neurotrophic axis in adult mice. Neurobiol Aging 2018,64,33-43","journal-title":"Neurobiol Aging"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1177\/2042018814559725","volume":"6","author":"Trujillo J.M.","year":"2015","unstructured":"Trujillo J.M.; Nuffer W.; Ellis S.L.; GLP-1 receptor agonists: a review of head-to-head clinical studies. Ther Adv Endocrinol Metab 2015,6(1),19-28","journal-title":"Ther Adv Endocrinol Metab"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-2202-13-33","volume":"13","author":"Hunter K.","year":"2012","unstructured":"Hunter K.; H\u00f6lscher C.; Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci 2012,13,33","journal-title":"BMC Neurosci"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/sj.ijo.0802206","volume":"27","author":"Kastin A.J.","year":"2003","unstructured":"Kastin A.J.; Akerstrom V.; Entry of exendin-4 into brain is rapid but may be limited at high doses. Int J Obes Relat Metab Disord 2003,27(3),313-318","journal-title":"Int J Obes Relat Metab Disord"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1111\/fcp.12192","volume":"30","author":"Gumuslu E.","year":"2016","unstructured":"Gumuslu E.; Mutlu O.; Celikyurt I.K.; Ulak G.; Akar F.; Erden F.; Ertan M.; Exenatide enhances cognitive performance and upregulates neurotrophic factor gene expression levels in diabetic mice. Fundam Clin Pharmacol 2016,30(4),376-384","journal-title":"Fundam Clin Pharmacol"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"112","DOI":"10.12659\/MSMBR.891168","volume":"20","author":"Komsuoglu Celikyurt I.","year":"2014","unstructured":"Komsuoglu Celikyurt I.; Mutlu O.; Ulak G.; Uyar E.; Bekta\u015f E.; Yildiz Akar F.; Erden F.; Tarkun I.; Exenatide treatment exerts anxiolytic- and antidepressant-like effects and reverses neuropathy in a mouse model of type-2 diabetes. Med Sci Monit Basic Res 2014,20,112-117","journal-title":"Med Sci Monit Basic Res"},{"key":"ref=115","first-page":"2861","volume":"17","author":"Bu\u0142dak \u0141.","year":"2019","unstructured":"Bu\u0142dak \u0141.; Machnik G.; Skudrzyk E.; Bo\u0142dys A.; Okopie\u0144 B.; The impact of exenatide (a GLP-1 agonist) on markers of inflammation and oxidative stress in normal human astrocytes subjected to various glycemic conditions. Exp Ther Med 2019,17(4),2861-2869","journal-title":"Exp Ther Med"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1530\/JOE-18-0639","volume":"242","author":"Xian Y.","year":"2019","unstructured":"Xian Y.; Chen Z.; Deng H.; Cai M.; Liang H.; Xu W.; Jianping W.; Xu F.; Exenatide mitigates inflammation and hypoxia along with improved angiogenesis in obese fat tissue. J Endocrinol 2019,242(2),79-89","journal-title":"J Endocrinol"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.cbi.2019.03.012","volume":"304","author":"Fang J.","year":"2019","unstructured":"Fang J.; Tang Y.; Cheng X.; Wang L.; Cai C.; Zhang X.; Liu S.; Li P.; Exenatide alleviates adriamycin-induced heart dysfunction in mice: Modulation of oxidative stress, apoptosis and inflammation. Chem Biol Interact 2019,304,186-193","journal-title":"Chem Biol Interact"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.peptides.2014.08.014","volume":"61","author":"Lennox R.","year":"2014","unstructured":"Lennox R.; Flatt P.R.; Gault V.A.; Lixisenatide improves recognition memory and exerts neuroprotective actions in high-fat fed mice. Peptides 2014,61,38-47","journal-title":"Peptides"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.neuropharm.2014.07.015","volume":"86","author":"McClean P.L.","year":"2014","unstructured":"McClean P.L.; H\u00f6lscher C.; Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer\u2019s disease. Neuropharmacology 2014,86,241-258","journal-title":"Neuropharmacology"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.bbrc.2018.11.135","volume":"508","author":"Zhao Z.","year":"2019","unstructured":"Zhao Z.; Pu Y.; Lixisenatide enhances mitochondrial biogenesis and function through regulating the CREB\/PGC-1\u03b1 pathway. Biochem Biophys Res Commun 2019,508(4),1120-1125","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.bbrc.2017.11.114","volume":"495","author":"Cai H-Y.","year":"2018","unstructured":"Cai H-Y.; Yang J-T.; Wang Z-J.; Zhang J.; Yang W.; Wu M-N.; Qi J-S.; Lixisenatide reduces amyloid plaques, neurofibrillary tangles and neuroinflammation in an APP\/PS1\/tau mouse model of Alzheimer\u2019s disease. Biochem Biophys Res Commun 2018,495(1),1034-1040","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=122","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2019.105732","volume":"75","author":"Du X.","year":"2019","unstructured":"Du X.; Zhang H.; Zhang W.; Wang Q.; Wang W.; Ge G.; Bai J.; Guo X.; Zhang Y.; Jiang X.; Gu J.; Xu Y.; Geng D.; The protective effects of lixisenatide against inflammatory response in human rheumatoid arthritis fibroblast-like synoviocytes. Int Immunopharmacol 2019,75","journal-title":"Int Immunopharmacol"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1080\/21691401.2019.1620248","volume":"47","author":"Zhao Q.","year":"2019","unstructured":"Zhao Q.; Xu H.; Zhang L.; Liu L.; Wang L.; GLP-1 receptor agonist lixisenatide protects against high free fatty acids-induced oxidative stress and inflammatory response. Artif Cells Nanomed Biotechnol 2019,47(1),2325-2332","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ejphar.2016.02.003","volume":"774","author":"Kamble M.","year":"2016","unstructured":"Kamble M.; Gupta R.; Rehan H.S.; Gupta L.K.; Neurobehavioral effects of liraglutide and sitagliptin in experimental models. Eur J Pharmacol 2016,774,64-70","journal-title":"Eur J Pharmacol"},{"key":"ref=125","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158205","volume":"11","author":"Hansen H.H.","year":"2016","unstructured":"Hansen H.H.; Fabricius K.; Barkholt P.; Kongsbak-Wismann P.; Schlumberger C.; Jelsing J.; Terwel D.; Termont A.; Pyke C.; Knudsen L.B.; Vrang N.; Long-term treatment with liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has no effect on \u03b2-amyloid plaque load in two transgenic APP\/PS1 mouse models of Alzheimer\u2019s disease. PLoS One 2016,11(7)","journal-title":"PLoS One"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2147\/CPAA.S164785","volume":"10","author":"Perna S.","year":"2018","unstructured":"Perna S.; Mainardi M.; Astrone P.; Gozzer C.; Biava A.; Bacchio R.; Spadaccini D.; Solerte S.B.; Rondanelli M.; 12-month effects of incretins versus SGLT-2 inhibitors on cognitive performance and metabolic profile. A randomized clinical trial in the elderly with Type-2 diabetes mellitus. Clin Pharmacol 2018,10,141-151","journal-title":"Clin Pharmacol"},{"key":"ref=127","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212283","volume":"4","author":"Prasad-Reddy L.","year":"2015","unstructured":"Prasad-Reddy L.; Isaacs D.; A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. Drugs Context 2015,4","journal-title":"Drugs Context"},{"key":"ref=128","first-page":"509","volume":"35","author":"Pathak R.","year":"2010","unstructured":"Pathak R.; Bridgeman M.B.; Dipeptidyl peptidase-4 (DPP-4) inhibitors in the management of diabetes. P 2010,35(9),509-513","journal-title":"P"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1111\/j.1463-1326.2010.01212.x","volume":"12","author":"Scheen A.J.","year":"2010","unstructured":"Scheen A.J.; Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab 2010,12(8),648-658","journal-title":"Diabetes Obes Metab"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1111\/1440-1681.12455","volume":"42","author":"Chen X-W.","year":"2015","unstructured":"Chen X-W.; He Z-X.; Zhou Z-W.; Yang T.; Zhang X.; Yang Y-X.; Duan W.; Zhou S-F.; Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus. Clin Exp Pharmacol Physiol 2015,42(10),999-1024","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"165","DOI":"10.4239\/wjd.v9.i10.165","volume":"9","author":"Hamasaki H.","year":"2018","unstructured":"Hamasaki H.; Hamasaki Y.; Efficacy of anagliptin as compared to linagliptin on metabolic parameters over 2 years of drug consumption: A retrospective cohort study. World J Diabetes 2018,9(10),165-171","journal-title":"World J Diabetes"},{"key":"ref=132","first-page":"613","volume":"64","author":"Sakr H.F.","year":"2013","unstructured":"Sakr H.F.; Effect of sitagliptin on the working memory and reference memory in type 2 diabetic Sprague-Dawley rats: possible role of adiponectin receptors 1. J Physiol Pharmacol 2013,64(5),613-623","journal-title":"J Physiol Pharmacol"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/dom.12432","volume":"17","author":"Gault V.A.","year":"2015","unstructured":"Gault V.A.; Lennox R.; Flatt P.R.; Sitagliptin, a dipeptidyl peptidase-4 inhibitor, improves recognition memory, oxidative stress and hippocampal neurogenesis and upregulates key genes involved in cognitive decline. Diabetes Obes Metab 2015,17(4),403-413","journal-title":"Diabetes Obes Metab"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1080\/01616412.2018.1474840","volume":"40","author":"Li J.","year":"2018","unstructured":"Li J.; Zhang S.; Li C.; Li M.; Ma L.; Sitagliptin rescues memory deficits in Parkinsonian rats via upregulating BDNF to prevent neuron and dendritic spine loss. Neurol Res 2018,40(9),736-743","journal-title":"Neurol Res"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1530\/JOE-12-0521","volume":"218","author":"Pintana H.","year":"2013","unstructured":"Pintana H.; Apaijai N.; Chattipakorn N.; Chattipakorn S.C.; DPP-4 inhibitors improve cognition and brain mitochondrial function of insulin-resistant rats. J Endocrinol 2013,218(1),1-11","journal-title":"J Endocrinol"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/ddr.21567","volume":"80","author":"Li Y.","year":"2019","unstructured":"Li Y.; Tian Q.; Li Z.; Dang M.; Lin Y.; Hou X.; Activation of Nrf2 signaling by sitagliptin and quercetin combination against \u03b2-amyloid induced Alzheimer\u2019s disease in rats. Drug Dev Res 2019,80(6),837-845","journal-title":"Drug Dev Res"},{"key":"ref=137","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/6091014","volume":"2018","author":"Wici\u0144ski M.","year":"2018","unstructured":"Wici\u0144ski M.; W\u00f3dkiewicz E.; S\u0142upski M.; Walczak M.; Socha M.; Malinowski B.; Pawlak-Osi\u0144ska K.; Neuroprotective activity of sitagliptin via reduction of neuroinflammation beyond the incretin effect: focus on Alzheimer\u2019s disease. BioMed Res Int 2018,2018","journal-title":"BioMed Res Int"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.neuint.2017.10.006","volume":"115","author":"Nader M.A.","year":"2018","unstructured":"Nader M.A.; Ateyya H.; El-Shafey M.; El-Sherbeeny N.A.; Sitagliptin enhances the neuroprotective effect of pregabalin against pentylenetetrazole-induced acute epileptogenesis in mice: Implication of oxidative, inflammatory, apoptotic and autophagy pathways. Neurochem Int 2018,115,11-23","journal-title":"Neurochem Int"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1159\/000490688","volume":"43","author":"Jo C.H.","year":"2018","unstructured":"Jo C.H.; Kim S.; Park J-S.; Kim G-H.; Anti-inflammatory action of sitagliptin and linagliptin in doxorubicin nephropathy. Kidney Blood Press Res 2018,43(3),987-999","journal-title":"Kidney Blood Press Res"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.2174\/1871527315666161003125752","volume":"15","author":"Shaikh S.","year":"2016","unstructured":"Shaikh S.; Rizvi S.M.D.; Suhail T.; Shakil S.; Abuzenadah A.M.; Anis R.; Naaz D.; Dallol A.; Haneef M.; Ahmad A.; Choudhary L.; Prediction of anti-diabetic drugs as dual inhibitors against acetylcholinesterase and beta-secretase: a neuroinformatics study. CNS Neurol Disord Drug Targets 2016,15(10),1216-1221","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/jdi.12847","volume":"10","author":"Anno T.","year":"2019","unstructured":"Anno T.; Kaneto H.; Kawasaki F.; Shigemoto R.; Aoyama Y.; Kaku K.; Okimoto N.; Drug fever and acute inflammation from hypercytokinemia triggered by dipeptidyl peptidase-4 inhibitor vildagliptin. J Diabetes Investig 2019,10(1),182-185","journal-title":"J Diabetes Investig"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"5100","DOI":"10.3892\/etm.2018.6016","volume":"15","author":"Zhang D-D.","year":"2018","unstructured":"Zhang D-D.; Shi N.; Fang H.; Ma L.; Wu W-P.; Zhang Y-Z.; Tian J-L.; Tian L-B.; Kang K.; Chen S.; Vildagliptin, a DPP4 inhibitor, alleviates diabetes-associated cognitive deficits by decreasing the levels of apoptosis-related proteins in the rat hippocampus. Exp Ther Med 2018,15(6),5100-5106","journal-title":"Exp Ther Med"},{"key":"ref=143","first-page":"4113","volume":"17","author":"Ma Q-H.","year":"2018","unstructured":"Ma Q-H.; Jiang L-F.; Mao J-L.; Xu W-X.; Huang M.; Vildagliptin prevents cognitive deficits and neuronal apoptosis in a rat model of Alzheimer\u2019s disease. Mol Med Rep 2018,17(3),4113-4119","journal-title":"Mol Med Rep"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.taap.2017.08.005","volume":"333","author":"Sa-Nguanmoo P.","year":"2017","unstructured":"Sa-Nguanmoo P.; Tanajak P.; Kerdphoo S.; Jaiwongkam T.; Pratchayasakul W.; Chattipakorn N.; Chattipakorn S.C.; SGLT-2 inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats. Toxicol Appl Pharmacol 2017,333,43-50","journal-title":"Toxicol Appl Pharmacol"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"203","DOI":"10.4172\/2329-6607.1000203","volume":"6","author":"Sala L.L.","year":"2017","unstructured":"Sala L.L.; Genovese S.; Ceriello A.; Effect of vildagliptin, compared to sitagliptin, on the onset of hyperglycemia-induced metabolic memory in human umbilical vein endothelial cells. Cardiovasc Pharm Open Access 2017,6(1),203","journal-title":"Cardiovasc Pharm Open Access"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13098-015-0087-3","volume":"7","author":"Tang Y-Z.","year":"2015","unstructured":"Tang Y-Z.; Wang G.; Jiang Z-H.; Yan T-T.; Chen Y-J.; Yang M.; Meng L-L.; Zhu Y-J.; Li C-G.; Li Z.; Yu P.; Ni C-L.; Efficacy and safety of vildagliptin, sitagliptin, and linagliptin as add-on therapy in Chinese patients with T2DM inadequately controlled with dual combination of insulin and traditional oral hypoglycemic agent. Diabetol Metab Syndr 2015,7,91","journal-title":"Diabetol Metab Syndr"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.diabres.2016.12.010","volume":"123","author":"Isik A.T.","year":"2017","unstructured":"Isik A.T.; Soysal P.; Yay A.; Usarel C.; The effects of sitagliptin, a DPP-4 inhibitor, on cognitive functions in elderly diabetic patients with or without Alzheimer\u2019s disease. Diabetes Res Clin Pract 2017,123,192-198","journal-title":"Diabetes Res Clin Pract"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1210\/jc.2009-0473","volume":"95","author":"Nair S.","year":"2010","unstructured":"Nair S.; Wilding J.P.H.; Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metab 2010,95(1),34-42","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta21020","volume":"21","author":"Johnston R.","year":"2017","unstructured":"Johnston R.; Uthman O.; Cummins E.; Clar C.; Royle P.; Colquitt J.; Tan B.K.; Clegg A.; Shantikumar S.; Court R.; O\u2019Hare J.P.; McGrane D.; Holt T.; Waugh N.; Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation. Health Technol Assess 2017,21(2),1-218","journal-title":"Health Technol Assess"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s40265-018-0878-6","volume":"78","author":"Markham A.","year":"2018","unstructured":"Markham A.; Ertugliflozin: first global approval. Drugs 2018,78(4),513-519","journal-title":"Drugs"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"447","DOI":"10.2174\/18715273113126660160","volume":"13","author":"Rizvi S.M.D.","year":"2014","unstructured":"Rizvi S.M.D.; Shakil S.; Biswas D.; Shakil S.; Shaikh S.; Bagga P.; Kamal M.A.; Invokana (Canagliflozin) as a dual inhibitor of acetylcholinesterase and sodium glucose co-transporter 2: advancement in Alzheimer\u2019s disease- diabetes type 2 linkage via an enzoinformatics study. CNS Neurol Disord Drug Targets 2014,13(3),447-451","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/bab.1319","volume":"63","author":"Shaikh S.","year":"2016","unstructured":"Shaikh S.; Rizvi S.M.D.; Shakil S.; Riyaz S.; Biswas D.; Jahan R.; Forxiga (dapagliflozin): plausible role in the treatment of diabetes-associated neurological disorders. Biotechnol Appl Biochem 2016,63(1),145-150","journal-title":"Biotechnol Appl Biochem"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.cbi.2017.08.013","volume":"277","author":"Arafa N.M.S.","year":"2017","unstructured":"Arafa N.M.S.; Ali E.H.A.; Hassan M.K.; Canagliflozin prevents scopolamine-induced memory impairment in rats: Comparison with galantamine hydrobromide action. Chem Biol Interact 2017,277,195-203","journal-title":"Chem Biol Interact"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"9887","DOI":"10.1038\/s41598-019-46402-6","volume":"9","author":"Shibusawa R.","year":"2019","unstructured":"Shibusawa R.; Yamada E.; Okada S.; Nakajima Y.; Bastie C.C.; Maeshima A.; Kaira K.; Yamada M.; Dapagliflozin rescues endoplasmic reticulum stress-mediated cell death. Sci Rep 2019,9(1),9887","journal-title":"Sci Rep"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12933-014-0148-1","volume":"13","author":"Lin B.","year":"2014","unstructured":"Lin B.; Koibuchi N.; Hasegawa Y.; Sueta D.; Toyama K.; Uekawa K.; Ma M.; Nakagawa T.; Kusaka H.; Kim-Mitsuyama S.; Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice. Cardiovasc Diabetol 2014,13,148","journal-title":"Cardiovasc Diabetol"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ejphar.2016.11.028","volume":"794","author":"Naznin F.","year":"2017","unstructured":"Naznin F.; Sakoda H.; Okada T.; Tsubouchi H.; Waise T.M.Z.; Arakawa K.; Nakazato M.; Canagliflozin, a sodium glucose cotransporter 2 inhibitor, attenuates obesity-induced inflammation in the nodose ganglion, hypothalamus, and skeletal muscle of mice. Eur J Pharmacol 2017,794,37-44","journal-title":"Eur J Pharmacol"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1530\/JOE-17-0263","volume":"234","author":"Millar P.","year":"2017","unstructured":"Millar P.; Pathak N.; Parthsarathy V.; Bjourson A.J.; O\u2019Kane M.; Pathak V.; Moffett R.C.; Flatt P.R.; Gault V.A.; Metabolic and neuroprotective effects of dapagliflozin and liraglutide in diabetic mice. J Endocrinol 2017,234(3),255-267","journal-title":"J Endocrinol"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.4155\/fmc-2018-0514","volume":"11","author":"Loutradis C.","year":"2019","unstructured":"Loutradis C.; Papadopoulou E.; Theodorakopoulou M.; Karagiannis A.; Sarafidis P.; The effect of SGLT-2 inhibitors on blood pressure: a pleiotropic action favoring cardio- and nephroprotection. Future Med Chem 2019,11(11),1285-1303","journal-title":"Future Med Chem"},{"key":"ref=159","unstructured":"Swiss Institute of Bioinformatics. Available at:"},{"key":"ref=160","year":"2018","unstructured":"Chemaxon. Software solutions and services for chemistry"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1021\/cn100008c","volume":"1","author":"Wager T.T.","year":"2010","unstructured":"Wager T.T.; Hou X.; Verhoest P.R.; Villalobos A.; Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. ACS Chem Neurosci 2010,1(6),435-449","journal-title":"ACS Chem Neurosci"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jss.2015.09.035","volume":"201","author":"Mohey V.","year":"2016","unstructured":"Mohey V.; Singh M.; Puri N.; Kaur T.; Pathak D.; Singh A.P.; Sildenafil obviates ischemia-reperfusion injury-induced acute kidney injury through peroxisome proliferator-activated receptor \u03b3 agonism in rats. J Surg Res 2016,201(1),69-75","journal-title":"J Surg Res"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1161\/ATVBAHA.115.307011","volume":"36","author":"Sanada F.","year":"2016","unstructured":"Sanada F.; Kanbara Y.; Taniyama Y.; Otsu R.; Carracedo M.; Ikeda-Iwabu Y.; Muratsu J.; Sugimoto K.; Yamamoto K.; Rakugi H.; Morishita R.; Induction of angiogenesis by a type III phosphodiesterase inhibitor, cilostazol, through activation of peroxisome proliferator-activated receptor-\u03b3 and camp pathways in vascular cells. Arterioscler Thromb Vasc Biol 2016,36(3),545-552","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"673","DOI":"10.2174\/0929867324666170116125159","volume":"24","author":"Jankowska A.","year":"2017","unstructured":"Jankowska A.; \u015awierczek A.; Ch\u0142o\u0144-Rzepa G.; Paw\u0142owski M.; Wyska E.; PDE7-selective and dual inhibitors: advances in chemical and biological research. Curr Med Chem 2017,24(7),673-700","journal-title":"Curr Med Chem"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"122","DOI":"10.2174\/1389450119666180808105056","volume":"20","author":"Jankowska A.","year":"2019","unstructured":"Jankowska A.; \u015awierczek A.; Wyska E.; Gawalska A.; Bucki A.; Paw\u0142owski M.; Ch\u0142o\u0144-Rzepa G.; Advances in discovery of PDE10A inhibitors for CNS-related disorders. Part 1: overview of the chemical and biological research. Curr Drug Targets 2019,20(1),122-143","journal-title":"Curr Drug Targets"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/175586","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/175586\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/175586","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T05:01:45Z","timestamp":1625202105000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/175586\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,24]]},"references-count":165,"journal-issue":{"issue":"39","published-print":{"date-parts":[[2020,11,24]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867326666191011144818","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11,24]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-05-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-08","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}